European research on cell and organ transplantation: towards novel opportunities?
European research on cell and organ transplantation: towards novel opportunities?
复制标题
欧洲细胞和器官移植研究：寻找新机遇？
DOI：
10.1111/j.1432-2277.2007.00554.x
复制
发表时间：
2007
影响因子：
3.1
通讯作者：
K. Wood
中科院分区：
文献类型：
--
作者：
M. Goldman;K. Wood
基础和转化免疫学的最新发展为临床细胞和器官移植开辟了新的令人兴奋的前景，包括开发新型免疫抑制剂，新的诊断工具和验证生物标志物用于预测排斥反应以及诱导耐受。关于耐受性，在实体器官移植受者中安全地最小化或撤回免疫抑制药物之前，仍需要克服许多障碍。事实上，人类免疫系统对耐受性诱导的抵抗力似乎比动物实验研究所预期的更强。此外，基本的伦理原则“primum non‐ percusere”防止实施对移植物和/或患者生存具有重大风险的临床方案。在此背景下，欧盟委员会最近启动了几项举措，以解决移植医学中未满足的需求。在此，我们将重点放在整个欧盟正在进行的合作努力，旨在确定当前的优先事项，需要更好地整合专门用于移植研究的资源。
Recent developments in basic and translational immunology open new exciting perspectives for clinical cell and organ transplantation, including the development of novel immunosuppressive agents, new diagnostic tools and validation of biomarkers for the prediction of rejection as well as the induction of tolerance. With respect to tolerance, a number of hurdles still need to be overcome before immunosuppressive drugs can be safely minimized or withdrawn in solid organ transplant recipients. Indeed, the human immune system appears more resistant to tolerance induction than expected from experimental studies in animals. Furthermore, the basic ethical principle ‘primum non‐nocere’ prevents the implementation of clinical protocols endowed with a significant risk for graft and/or patient survival. With this background, the European Commission recently launched several initiatives to tackle unmet needs in transplantation medicine. Herein, we focus attention on the ongoing collaborative effort across the European Union aiming at identifying the current priorities requiring better integration of resources dedicated to transplantation research.